Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Depreciation and Depletion: 2021-2025

Historic Depreciation and Depletion for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to $784,436.

  • ProQR Therapeutics N.V's Depreciation and Depletion rose 3.82% to $784,436 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 2.50%. This contributed to the annual value of $3.0 million for FY2024, which is 8.54% up from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Depreciation and Depletion stood at $784,436 for Q3 2025, which was up 2.67% from $764,073 recorded in Q2 2025.
  • ProQR Therapeutics N.V's 5-year Depreciation and Depletion high stood at $784,436 for Q3 2025, and its period low was $589,265 during Q1 2023.
  • In the last 3 years, ProQR Therapeutics N.V's Depreciation and Depletion had a median value of $750,676 in 2024 and averaged $724,443.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first decreased by 15.95% in 2022, then rose by 27.39% in 2024.
  • Over the past 5 years, ProQR Therapeutics N.V's Depreciation and Depletion (Quarterly) stood at $631,472 in 2021, then increased by 20.85% to $763,145 in 2022, then increased by 2.64% to $783,284 in 2023, then fell by 8.46% to $717,027 in 2024, then climbed by 3.82% to $784,436 in 2025.
  • Its Depreciation and Depletion was $784,436 in Q3 2025, compared to $764,073 in Q2 2025 and $713,178 in Q1 2025.